Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2022 | How GvHD impacts patient quality of life

Shernan Holtan • 10 Dec 2022

ASH 2022

General

BMT CTN 1703

In this video, Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, briefly explains how graft-versus-host disease (GvHD) can affect a patient’s quality of life (QoL). GvHD can result in mobility issues, an increased risk of infection, and other serious complications, and Dr Holtan further highlights the importance of analyzing QoL data in ongoing clinical trials. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Incyte: Research Funding; Vitrac Therapeutics: Research Funding; CSL Behring: Other: Clinical trial adjudication.

Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting

Shernan Holtan • 10 Dec 2022

Unmet needs in GvHD & the promise of regenerative medicine

Shernan Holtan • 10 Dec 2022

ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RIC

Shernan Holtan • 10 Dec 2022

Repurposing drugs for the treatment of acute GvHD

Shernan Holtan • 25 Apr 2022

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives

Claire Horgan • 15 Apr 2024